Immunogenicity and safety of an intramuscular A/H5N1 inactivated, split virion pandemic influenza vaccine in adults

Trial Profile

Immunogenicity and safety of an intramuscular A/H5N1 inactivated, split virion pandemic influenza vaccine in adults

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 24 Sep 2008 Primary outcome amended as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Actual end date added as 1 Sep 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top